The major hallmark of Parkinson's disease (PD) is the progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the characteristic motor symptoms of resting tremors, bradykinesia and rigidity. Research in the field of PD therapy has been partly successful in terms of developing symptomatic treatments, but it also experienced several failures with regard to developing disease-modifying therapies. According to the definition of the Committee to Identify Neuroprotective Agents for Parkinson's, neuroprotection would be any intervention that favorably influences the disease process or underlying pathogenesis to produce enduring benefits for patients. A development of effective neuroprotective therapies resulting in clinically meaningful results is hampered by several factors in all research stages. Novel solutions might be offered by an evaluation of new targets throughout clinical studies, therapies emerging from drug repositioning approaches, multitarget approaches and network pharmacology. Several promising randomized controlled trials are in progress, and the increased collaboration between pharmaceutical companies and basic and clinical researchers has the potential to bring us closer to developing an optimum pharmaceutical approach for the treatment of PD. The aim of the present review is to give an overview of the neuroprotective agents and their targets currently investigated for the treatment of PD in phase I-III clinical trials.

Keywords:
Parkinson’s disease, Motor disorder, Clinical trials, Phase I, Phase II, Phase III
1.
Thomas B: Parkinson's disease: from molecular pathways in disease to therapeutic approaches. Antioxid Redox Signal 2009;9:2077-2082.
2.
Parkinson J: An essay on the shaking palsy. J Neuropsychiatry Clin Neurosci 1817;14:223-236, discussion 222.
3.
Skibinski G, Finkbeiner S: Drug discovery in Parkinson‘s disease: update and developments in the use of cellular models. Int J High Throughput Screen 2011;2011:15-25.
4.
Thomas B, Beal F: Parkinson's disease. Hum Mol Genet 2007;16:R183-R194.
5.
Hwang O: Role of oxidative stress in Parkinson's disease. Exp Neurobiol 2013;1:11-17.
6.
Klucken J, Barth J, Kugler P, Schlachetzki J, Henze T, Marxreiter F, Kohl Z, Steidl R, Hornegger J, Eskofier B, Winkler J: Unbiased and mobile gait analysis detects motor impairment in Parkinson's disease. PLoS One 2013;8:e56956.
7.
Chaudhuri KR, Healy DG, Schapira AHV: Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-245.
8.
Sherer TB, Betarbet R, Greenamyre JT: Pathogenesis of Parkinson's disease. Curr Opin Investig Drugs 2001;2:657-662.
9.
Dexter DT, Jenner P: Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 2013;62:132-144.
10.
Gandhi S, Wood NW: Molecular pathogenesis of Parkinson's disease. Hum Mol Genet 2005;14(spec No):2749-2755.
11.
Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, Hashida H, Kubo S, Suzuki M, Nanri K, Matsumura M, Murakami H, Hattori N: Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Intern Med 2013;52:325-332.
12.
Schneider JS, Pope A, Simpson K, Taggart J, Smith MG, DiStefano L: Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment. Science 1992;256:843-846.
13.
Pope-Coleman A, Tinker JP, Schneider JS: Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys. Synapse 2000;36:120-128.
14.
GM1 ganglioside effects on Parkinson's disease. http://www.clinicaltrials.gov/ct2/show/NCT00037830?term=nct00037830&rank=1.
16.
ADX48621 for the treatment of levodopa induced dyskinesia in patients with Parkinson's disease. http://www.clinicaltrials.gov/ct2/show/NCT01336088?term=nct01336088&rank=1.
17.
A trial of MitoQ for the treatment of people with Parkinson's disease. http://www.clinicaltrials.gov/ct2/show/NCT00329056?term=nct00329056&rank=1.
18.
Gregoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, di Paolo T: The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-dopa-treated parkinsonian monkeys. Parkinsonism Relat Disord 2011;17:270-276.
19.
Efficacy and safety of AFQ056 when combined with increased doses of L-dopa in Parkinson's disease patients with moderate-severe L-dopa induced dyskinesia. http://www.clinicaltrials.gov/ct2/show/NCT01092065?term=nct01092065&rank=1.
20.
Dose-finding safety study of BIIB014 in early-stage Parkinson's disease (MOBILE). http://www.clinicaltrials.gov/ct2/show/NCT00442780?term=nct00442780&rank=1.
21.
Study of the effect of SR57667B on 18F-dopa PET imaging in patients with Parkinson's disease. http://www.clinicaltrials.gov/ct2/show/NCT00220272?term=nct00220272&rank=1.
22.
Breidert T, Callebert J, Heneka MT, Landreth G, Launay JM, Hirsch EC: Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 2002;82:615-624.
24.
Eggert D, Dash PK, Gorantla S, Dou H, Schifitto G, Maggirwar SB, Dewhurst S, Poluektova L, Gelbard HA, Gendelman HE: Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol 2010;184:746-756.
25.
Safety and efficacy study of CEP-1347 in the treatment of Parkinson's disease. http://www.clinicaltrials.gov/ct2/show/NCT00040404?term=nct00040404&rank=1.
26.
Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM: Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord 2005;20:403-409.
27.
Topiramate as a treatment for levodopa-induced dyskinesia in Parkinson's disease. http://www.clinicaltrials.gov/ct2/show/NCT00296959?term=nct00296959&rank=1.
28.
A pilot study to assess efficacy and safety of pardoprunox as adjunct therapy to L-dopa in the treatment of patients with Parkinson's disease experiencing motor fluctuations and dyskinesia. http://www.clinicaltrials.gov/ct2/show/NCT00903838?term=nct00903838&rank=1.
29.
Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, Salvati P, Fariello RG: Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67(suppl 2):S18-S23.
30.
Open-label trial to determine the long-term safety of safinamide in Parkinson's disease patients. http://www.clinicaltrials.gov/ct2/show/NCT00865579?term=NCT00865579&rank=1.
31.
Extended release amantadine safety and efficacy study in levodopa-induced dyskinesia (EASED Study). http://www.clinicaltrials.gov/ct2/show/NCT01397422?term=nct01397422&rank=1.
32.
A study to evaluate the safety and efficacy of IPX066 in subjects with Parkinson's disease (APEX-PD). http://www.clinicaltrials.gov/ct2/show/NCT00880620?term=NCT00880620&rank=1.
33.
Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K: Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. Lancet Neurol 2011;10:221-229.
34.
An active-controlled extension study to P04938 and P07037 (P06153 AM3). http://www.clinicaltrials.gov/ct2/show/NCT01215227?term=nct01215227&rank=1.
35.
Caffeine as a therapy for Parkinson's disease. http://www.clinicaltrials.gov/ct2/show/NCT01738178?term=nct01738178&rank=1.
36.
Murata M, Horiuchi E, Kanazawa I: Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 2001;41:397-399.
37.
Study of zonisamide in early Parkinson disease (ZONIST). http://www.clinicaltrials.gov/ct2/show/NCT01766128?term=nct01766128&rank=1.
38.
Efficacy, safety and tolerability of E2007 in levodopa-treated Parkinson's disease patients with motor fluctuations. http://www.clinicaltrials.gov/ct2/show/NCT00360308?term=nct00360308&rank=1.
39.
Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB: Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol 1985;116:313-317.
40.
Akao Y, Maruyama W, Yi H, Shamoto-Nagai M, Youdim MB, Naoi M: An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 2002;326:105-108.
41.
Efficacy, tolerability and safety of azilect in subjects with progressive supranuclear palsy (PROSPERA). http://www.clinicaltrials.gov/ct2/show/NCT01187888?term=NCT01187888&rank=1.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.